The J-Valve transcatheter mitral valve intervention animal training, organized by JianShi JieCheng, was held at GuoRui XinChuang.
Release time:
2022-10-09 14:14
Keywords:
The J-Valve Transcatheter Heart Valve Animal Experiment Training Workshop, organized by JianShiJieCheng, was held at GuoRui XinChuang.
2022 In September, Suzhou Jiecheng Medical Technology Co., Ltd., part of JianShi Medical Technology Group, invited Dr. Yang Jian from Xijing Hospital to hold the “4th J-Valve Transapical Interventional Cardiac Valve Animal Experiment Training” for 2022 at the conference room of Shaanxi Guorui Xin Chuang Medical Technology Co., Ltd.
After the training concluded, Suzhou Jiecheng Medical Technology Co., Ltd. of JianShi Medical Technology Group organized the trainees to conduct hands-on practice in transcatheter aortic valve replacement (TAVR) procedures at the Guorui XinChuang Animal Experiment Center, and presented medals and certificates of honor to the outstanding trainees.
Dr. Yang Jian’s Biography:
Yang Jian is the Associate Director of Cardiovascular Surgery at Xijing Hospital and a doctoral supervisor. He is a Fellow of the American Heart Association (FACC), a Fellow of the American College of Cardiology (FAHA), and Vice Chairman of the Structural Heart Disease Professional Committee of the Cardiovascular Surgeons Branch of the Chinese Medical Association. He also serves as an editorial board member of the Chinese Journal of Thoracic and Cardiovascular Surgery. His clinical expertise lies in minimally invasive and interventional treatments for complex structural heart diseases. His primary research interests include novel diagnostic and therapeutic technologies for structural heart disease, as well as studies on myocardial cell injury repair, remodeling, and regeneration. He has achieved significant accomplishments in minimally invasive transcatheter valve replacement, cardiovascular device development, clinical translation, and multimodal imaging assessment centered on 3D printing. He has published over 30 SCI papers as first or corresponding author in journals such as Eur Heart J and JACC, with more than 500 citations. He has received awards including the Second Prize of the National Science and Technology Progress Award and the First Prize of the Chinese Medical Science and Technology Award. He has served as chief editor of 5 monographs and published 12 monographs and translated works.
Introduction to Suzhou Jiecheng Medical Technology Co., Ltd., a member of JianShi Medical Technology Group:
Suzhou Jiecheng Medical Technology Co., Ltd. was established in September 2009 and is a high-tech enterprise specializing in the R&D and manufacturing of high-end cardiovascular medical devices. The company boasts a strong R&D team led by Dr. Zhang Ji, a cardiac surgery expert, along with numerous domestic and international R&D specialists. It has obtained dozens of international PCT invention patents, and its innovative technologies are at the forefront internationally.
2022 In [year], Jiecheng Medical officially joined JianShi Medical Technology Group, giving rise to the Structural Heart Disease Division. The division’s mission is to establish unified standards for the clinical outcomes of structural heart disease and align these standards with international medical quality benchmarks. By doing so, it aims to guide the industry toward alignment with outstanding cardiovascular clinical and innovation teams around the world, delivering value-oriented healthcare services to society and promoting human well-being.
Jiecheng Medical, part of Jianshi Medical Technology Group, is a “leader” in China’s transcatheter aortic valve replacement (TAVR) field. Its flagship product, the “J-Valve,” is currently the only interventional valve device approved by the NMPA that can simultaneously treat both severe aortic valve regurgitation (insufficiency) and stenosis—offering dual indications. Jiecheng Medical’s next-generation product, the J-Valve transvascular intervention valve, has already provided life-saving assistance to dozens of patients internationally through the “humanitarian rescue” channels approved by health ministries in multiple countries. Moving forward, Jianshi’s Structural Heart Disease Business Unit will continue to expand its product portfolio to serve an even greater number of patients with structural heart disease.
Introduction to Shaanxi Guorui Xinchuang Medical Technology Co., Ltd.:
Shaanxi Guorui Xinchuang Medical Technology Co., Ltd. is an independent, third-party clinical preclinical safety evaluation research institution for medical devices. It was registered and established in June 2020 in the Airport New City Airside Industrial Park. Currently, it is the largest and most powerful medical device safety evaluation institution in Northwest China, primarily providing product safety evaluation services to R&D companies of Class II and Class III medical devices.
Guo Rui Xin Chuang obtained the “License for the Use of Laboratory Animals” issued by the Shaanxi Provincial Department of Science and Technology in March 2021. It is the only medical device preclinical evaluation laboratory in our province operating under GLP standards. Currently, Guo Rui Xin Chuang holds 6 software copyrights and was awarded the High-Tech Enterprise Certificate in July 2022.
As an important intermediate link in the transformation of innovative medical devices from the innovation chain to the industrial chain, medical device safety evaluation research bridges the interaction and integration between the innovation chain and the industrial chain in the life sciences sector under the Qin Chuang Yuan initiative, and thus holds significant value for the development of the province’s life sciences industry. 
(Guorui Xin Chuang Operating Room and Surgical Instruments & Equipment)
Related News
Contact phone number
Ms. Li:+86 15760970681
Mr. Su:+86 19991001701
Landline:+86-29-33656828
Company Address
4th Floor, Unit C. Building 9. Small and Medium-sized
Enterprise Park, Airport Industrial Zone Airport New Ciy,Xixian New Area, Shaanxi Province
©2026 Xixian New Area Guorui Yinuo Drug Safety Evaluation and Research Co., Ltd.
WhatsApp：8613940397353
Email：hr-xian@grglp.com
Landline：862933656828
Mr. Su：8619991001701
Ms. Li：8615760970681